ArticleSkin appendage disorders2025
Secondary Cutis Verticis Gyrata Induced by Long-Term Use of High-Dose Topical Minoxidil.
Article in Skin appendage disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cutis verticis gyrata (CVG) is a medical condition that is characterized by thickening of the scalp giving the scalp a cerebriform appearance. Due to an apparent paucity of the condition, limited research exists, and causes are as yet undetermined. What is known, is that the condition may either be a feature of several syndromes or occur as a consequence of a number of diseases or drugs that produce changes in scalp structure, particularly acromegaly, and theoretically, the use of growth hormone (GH) itself or the use of drugs that mimic the effect of GH (secretagogues). Case Presentation: We present a case of CVG that resulted from long-term topical use of minoxidil at a high concentration. Discussion and Conclusion: Minoxidil has been shown to be able to potentiate the mitogenic effects of insulin-like growth factor (IGF-1). Meanwhile, the striking manifestations of acromegaly are due to excessive IGF-1 production by the liver in response to GH stimulation. The growth-promoting properties of IGF-1 trigger soft tissue hypertrophy, and hypertrichosis. Pseudoacromegaly has been reported to be induced by the long-term use of oral minoxidil. This is the first case report of secondary CVG from the use of topical minoxidil for the treatment of male androgenetic alopecia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.